Androgens
Methenolone
A steroid with formulation-specific clinical case reports; neither a bone observation nor a mild reputation establishes general safety.
Clinical case reports; no comparative efficacy conclusion; evidence checked 2026-10-01
Also known as: Metenolone
Practical use
Evidence interpretation and concrete review questions
- Keep the diagnoses attached
- Blood and kidney disease materially affect interpretation.
- List co-treatments
- Do not assign a case’s entire course to one ingredient.
- Choose the meaningful outcome
- Bone density, fractures, anemia response and survival are separate.
Bone-density observation during anemia care
Overview
Methenolone is also spelled metenolone. Acetate and enanthate are distinct ester forms. The human reports summarized here concern methenolone acetate in people with serious blood disorders, not enhancement in healthy adults.
Risks and limitations
A published case attributed fatal liver failure most strongly to methenolone acetate in a medically complex patient. Attribution is not absolute proof, but it prevents treating severe toxicity as impossible.
How to read this
Single-patient benefit and harm observations both need context. Neither can provide an average effect or a reliable event rate.
Research explained
Bone-density observation during anemia care
Who was studied
One older man with stage 4 kidney disease and myelodysplastic syndrome, treated with methenolone acetate and darbepoetin.
What was found
Bone-density decline became less pronounced during anemia treatment.
What it cannot establish
Two treatments and multiple diseases prevent causal attribution; no control group or fracture-prevention result.
Read the original studySevere liver injury in aplastic anemia
Who was studied
A 75-year-old man with severe aplastic anemia and prior immunosuppressive/steroid treatment.
What was found
Liver abnormalities followed methenolone acetate, progressing to liver failure and death; autopsy supported drug-related injury.
What it cannot establish
Complex co-exposures and a single case cannot establish incidence or eliminate every alternative cause.
Read the original studyAn association is not a single-drug effect
The bone report included darbepoetin and changing clinical circumstances.
Supporting sourceName the ester
The acetate reports do not directly compare every methenolone formulation.
Supporting sourceClaims versus findings
Not defensible
A mild reputation excludes severe liver toxicity.
A documented severe case exists, despite uncertainty about its general frequency.
Check the evidenceCommon questions
Does slower bone-density decline prove fracture prevention?
No fractures-versus-control comparison was performed.
SourceLearn with Avery
Primo Is The Most Overrated Compound In Bodybuilding (Here's Why)
Sources
Bone-density observation during anemia care
Severe liver injury in aplastic anemia
PubChem chemical identity; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.